{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:53Z","timestamp":1794020033066,"version":"4.8.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,6]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The soluble interleukin-2 receptor was identified as an only independent prognostic factor for chronic and smoldering ATL in this study. The prognostic index using the values of sIL-2R (iATL-PI) is a promising tool for the risk-adapted therapeutic intervention.<\/jats:p>","DOI":"10.1182\/blood-2017-01-757542","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T21:05:23Z","timestamp":1495055123000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma"],"prefix":"10.1182","volume":"130","author":[{"given":"Hiroo","family":"Katsuya","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, Fukuoka, Japan;"},{"name":"Center for AIDS Research, Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, Fukuoka, Japan;"},{"name":"Division of Hematology and Immunology, Center for Chronic Viral Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Miyazaki University, Miyazaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hino","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization, Kagoshima Medical Center, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sasebo City General Hospital, Sasebo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaburo","family":"Sueoka","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization, Nagasaki Medical Center, Ohmura, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Suzushima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Miyahara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[{"name":"Cancer Center, Shimane University Hospital, Izumo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111904353610100_B1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"2019111904353610100_B2","first-page":"221","article-title":"Chemotherapy of ATL","volume-title":"Adult T-Cell Leukemia","author":"Shimoyama","year":"1994"},{"issue":"3","key":"2019111904353610100_B3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111904353610100_B4","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111904353610100_B5","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111904353610100_B6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111904353610100_B7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"34","key":"2019111904353610100_B8","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111904353610100_B9","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111904353610100_B10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111904353610100_B11","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111904353610100_B12","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111904353610100_B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111904353610100_B14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2141.2003.04054.x","article-title":"Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia\/lymphoma","volume":"120","author":"Kami","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111904353610100_B15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"2019111904353610100_B16","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111904353610100_B17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"issue":"34","key":"2019111904353610100_B18","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111904353610100_B19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.leukres.2006.10.017","article-title":"Clinical significance of a blood eosinophilia in adult T-cell leukemia\/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor","volume":"31","author":"Utsunomiya","year":"2007","journal-title":"Leuk Res"},{"issue":"22","key":"2019111904353610100_B20","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2019111904353610100_B21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111904353610100_B22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111904353610100_B23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111904353610100_B24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111904353610100_B25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"27","key":"2019111904353610100_B26","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111904353610100_B27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin\u2019s lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111904353610100_B28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00432-004-0600-9","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin\u2019s lymphoma: in combination with the International Prognostic Index","volume":"131","author":"Goto","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2019111904353610100_B29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/10428190500361029","article-title":"Aggressive non-Hodgkin\u2019s lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome","volume":"47","author":"Fabre-Guillevin","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111904353610100_B30","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R\u03b1 facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111904353610100_B31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1349-7006.1988.tb00028.x","article-title":"Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia\/lymphoma virus type-I seropositive healthy carriers","volume":"79","author":"Motoi","year":"1988","journal-title":"Jpn J Cancer Res"},{"issue":"4","key":"2019111904353610100_B32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V71.4.1021.1021","article-title":"Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease","volume":"71","author":"Yasuda","year":"1988","journal-title":"Blood"},{"issue":"5","key":"2019111904353610100_B33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/1043-4666(90)90062-X","article-title":"The molecular basis for the generation of the human soluble interleukin 2 receptor","volume":"2","author":"Rubin","year":"1990","journal-title":"Cytokine"},{"issue":"11","key":"2019111904353610100_B34","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/1097-0142(19940601)73:11<2753::AID-CNCR2820731117>3.0.CO;2-X","article-title":"Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia","volume":"73","author":"Kamihira","year":"1994","journal-title":"Cancer"},{"issue":"2","key":"2019111904353610100_B35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2249.2000.01136.x","article-title":"Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers","volume":"119","author":"Araki","year":"2000","journal-title":"Clin Exp Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/1\/39\/1402019\/blood757542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/1\/39\/1402019\/blood757542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:35:52Z","timestamp":1574138152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/1\/39\/36237\/Prognostic-index-for-chronic-and-smolderingtype"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-01-757542","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]}}}